News | September 10, 2010

First Patient Supported with Transcatheter Right Heart VAD

September 10, 2010 – The first patient was successfully supported for six days by the Impella Right Peripheral (RP) ventricular assist device (VAD) at the Providence Heart and Lung Institute at St. Paul’s Hospital in Vancouver, British Columbia. This is the first use of the Impella RP.

The procedure was performed by Anson Cheung, M.D., of the Providence Heart and Lung Institute. The Impella RP is available to this institution under “special access” regulations in Canada.

“We are thrilled to be the first institution in the world to use the Impella RP for support in a patient,” said Anson Cheung, M.D., surgical director of heart transplantation for the Providence Heart and Lung Institute at St. Paul’s Hospital. “A common challenge for post-transplant patients with acute right heart failure is that they often have limited treatment options. The Impella RP represents a huge step forward in offering right side support using a minimally invasive platform. Our organization excels in offering revolutionary cardiac care for patients and the Impella RP allows us to improve the overall quality of life for patients suffering from heart failure."

The Impella RP is a percutaneous, catheter-based, axial flow pump. It is inserted via a single access vessel and does not require the patient’s chest to be opened. It is passed through the right ventricle and delivers greater than 4 liters of blood flow per minute from the lower right atrium to the pulmonary artery.

Patients with right ventricular dysfunction or right heart failure, lack blood flow from the right side of their hearts. The Impella RP is intended to provide the flow and pressure needed to compensate for right heart failure. Right heart failure can occur either as an isolated event or can be associated with left heart failure when the patient is suffering from biventricular failure.

Similar to the Impella 2.5 and 5.0, the Impella RP can be inserted in the catheterization lab or in the surgery suite. Cardiologists and surgeons will be able to treat right heart dysfunction without opening the patient’s chest or requiring another surgery. Some patient populations that could potentially benefit from percutaneous right-sided support are: post operative right ventricular dysfunction following transplant, Left VAD placement for heart surgery, cardiogenic shock, isolated right side failure from chronic heart disease, and elevated pulmonary artery blood pressure following pulmonary embolism.

The Impella RP is currently not available in the United States.

For more information: www.abiomed.com

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD)| April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD)| March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD)| March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD)| March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init